Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Spahn

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Journal of Asthma and Allergy|October 14, 2024
Reduced Effectiveness of Anti-IgE Treatment Among Adults with Severe Asthma with Older Age of Asthma Onset: Results from the CHRONICLE StudyDennis K Ledford, Warner W Carr, Wendy C Moore, et al.
The European Respiratory Journal|March 30, 2023
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyondJonathan Corren, Christopher E Brightling, Louis-Philippe Boulet, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Journal of Asthma and Allergy|October 14, 2024
Reduced Effectiveness of Anti-IgE Treatment Among Adults with Severe Asthma with Older Age of Asthma Onset: Results from the CHRONICLE StudyDennis K Ledford, Warner W Carr, Wendy C Moore, et al.
The European Respiratory Journal|March 30, 2023
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyondJonathan Corren, Christopher E Brightling, Louis-Philippe Boulet, et al.
Pageof 2